Your search for apixaban returned 96 results

Improved communication with patients about cost, bleeding, and monitoring may increase compliance

Findings may help with decision-making in this high-risk patient population.

Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.

Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

Risks for ischemic stroke or systemic embolism, major bleeding events lower with DOACs overall as a class versus warfarin

Kidney injury may be less among patients with chronic kidney disease and atrial fibrillation taking apixaban versus warfarin for anticoagulation, new research suggests.

Adaptive design allows evaluation of various doses, types of blood thinners in outpatients, inpatients.